2024 Global Pharmaceutical Leaders: Ranking by Revenue Scale

The pharmaceutical sector stands as a vital pillar driving medical innovation and drug commercialization across the globe. Industry data reveals robust expansion, with the sector reaching approximately US$1.6 trillion in 2023, a substantial climb from US$1 billion just a decade prior. North America maintains its position as the primary growth engine, fueled by the dominant United States market. Prescription medication sales alone are projected to surpass US$1.7 trillion by 2030, underscoring the sector’s pivotal role in global healthcare.

Understanding which pharmaceutical companies command the largest market share provides valuable insight into industry leadership and innovation trajectories. The following analysis examines the ten biggest revenue generators reshaping the competitive landscape.

1. Johnson & Johnson: Maintaining Dominance

Revenue 2023: US$85.16 billion

Leading the pharmaceutical landscape is Johnson & Johnson, an integrated powerhouse spanning research, manufacturing, and commercialization across therapeutics and medical devices. Following the 2023 separation of its consumer health division into Kenvue, the company has sharpened its focus on five core therapeutic pillars: immunology, infectious disease vaccination, neuroscience, oncology, and cardiometabolic treatment.

The pharmaceutical giant demonstrated resilience through diversified portfolio performance. Its immunology cornerstone Stelara expanded from US$9.72 billion (2022) to US$10.86 billion (2023), while oncology divisions climbed 10.5 percent to US$17.66 billion. Notably, plaque psoriasis treatment Tremfya surged 18 percent year-over-year, reaching US$3.15 billion.

Management projects 5-7 percent annual growth through 2030, anchored by a pipeline potentially containing 10+ products capable of achieving peak sales exceeding US$5 billion each.

2. Roche Holding: Swiss Innovation Engine

Revenue 2023: US$65.32 billion

The Basel-based Roche Holding operates through dual divisions spanning diagnostics and pharmaceutical development. Despite a reported 7.2 percent revenue contraction (largely currency-driven), Roche secured the second-largest pharmaceutical company revenue position globally.

The portfolio’s standout performer is Vabysmo, an eye disease therapeutic positioned as a direct competitor to established ophthalmology treatments. Hemophilia A therapy Hemlibra accelerated 16 percent to US$4.6 billion in annual sales, demonstrating sustained commercial momentum in rare disease treatment.

3. Merck & Company: Growth Through Specialty Focus

Revenue 2023: US$60.1 billion

Despite modest 1.4 percent revenue growth, Merck ascended from fourth to third position within the global pharmaceutical ranking. The catalyst: unprecedented blockbuster performance of checkpoint inhibitor Keytruda, commanding the world’s top-selling pharmaceutical position at US$25 billion globally—a 19 percent year-over-year surge.

The oncology asset’s dominance introduces strategic risk, comprising 41 percent of total revenues heading toward 2028 patent expiration. Meanwhile, HPV vaccine Gardasil demonstrated counter-narrative strength, accelerating 29 percent to US$8.9 billion. Conversely, diabetes medications Januvia and Janumet contracted 25 percent as generic competition intensified and North American demand softened.

4. Pfizer: Navigating Post-Pandemic Transition

Revenue 2023: US$58.5 billion

Pfizer’s 2023 trajectory exemplifies sector volatility: revenues plummeted 41 percent as pandemic therapeutics demand normalized from the record US$100.33 billion achieved in 2022. Excluding COVID-19 product lines, the pharmaceutical company actually expanded drug sales 7 percent, signaling underlying portfolio resilience.

The December 2023 acquisition of Seagen for US$43 billion signals strategic repositioning toward sustainable oncology growth, marking a deliberate transition away from pandemic-driven revenue cycles.

5. AbbVie: Confronting Exclusivity Challenges

Revenue 2023: US$54.3 billion

AbbVie specializes across autoimmune, neurological, and metabolic disease verticals. Humira—historically one of pharmaceutical history’s bestselling treatments—now faces biosimilar encroachment following US market exclusivity loss. The company is strategically pivoting toward immunology assets Skyrizi and Rinvoq to sustain growth momentum.

6. Sanofi: Vaccine Leadership and Diversification

Revenue 2023: US$46.6 billion

France-based Sanofi operates as the world’s largest vaccine manufacturer via subsidiary Sanofi Pasteur, while maintaining diversified pharmaceutical portfolios spanning oncology, immunology, and rare diseases. The company advanced two positions on the ranking despite minimal 0.2 percent revenue growth. Dupixent—approved for atopic dermatitis in 2017—continues expanding into adjacent indications, driving consistent revenue acceleration.

7. AstraZeneca: Oncology-Powered Expansion

Revenue 2023: US$45.81 billion

AstraZeneca surpassed the US$40 billion revenue threshold in 2022 and continued gaining momentum, capturing seventh position through 3.3 percent growth. The oncology division emerged as primary growth engine, posting 20 percent expansion to US$17.1 billion.

Lung-cancer therapeutic Tagrisso generated US$5.8 billion (up 9 percent), while immuno-oncology compounds Imfinzi and Imjudo delivered combined US$4.2 billion in sales, expanding 55 percent year-over-year.

8. Novartis: Pure-Play Pivot

Revenue 2023: US$45.44 billion

Following its separation of generics and biosimilar operations (Sandoz spinoff), Novartis repositioned as a pure innovative medicines company. Revenue expansion of 7.7 percent—from US$42.21 billion in 2022—reflected strength in heart disease combination therapy Entresto and multiple sclerosis injection Kesimpta, each exceeding US$6 billion and US$2 billion respectively.

9. Bristol-Myers Squibb: Managing Patent Transitions

Revenue 2023: US$45 billion

Pharmaceutical developer Bristol-Myers Squibb experienced 2 percent revenue contraction, sliding from seventh to ninth position. The company navigates multiple headwinds: blockbuster Revlimid faces patent expiration, while regulatory pricing mechanisms (Inflation Reduction Act) threaten future growth. Management now emphasizes Eliquis and Opdivo momentum, anticipating meaningful IRA pricing impacts in 2026.

10. GSK: Vaccine-Driven Resurgence

Revenue 2023: US$38.4 billion

Completing the top-ten ranking, GSK maintains three operational pillars: pharmaceuticals, consumer healthcare, and vaccines. The company posted 3.4 percent revenue growth to US$38.4 billion, driven primarily by shingles vaccine Shingrix (17 percent acceleration). FDA-approved RSV vaccine Arexvy emerged as a significant new revenue stream, marking the world’s first RSV immunization for adults aged 60+.

The competitive landscape among leading pharmaceutical companies reflects industry-wide challenges including patent expirations, biosimilar competition, and regulatory pricing pressures, offset by innovation in oncology, immunology, and rare disease treatments.